Pasithea Therapeutics (KTTA) Common Equity (2021 - 2024)
Historic Common Equity for Pasithea Therapeutics (KTTA) over the last 4 years, with Q3 2024 value amounting to $17.8 million.
- Pasithea Therapeutics' Common Equity fell 3721.82% to $17.8 million in Q3 2024 from the same period last year, while for Sep 2024 it was $17.8 million, marking a year-over-year decrease of 3721.82%. This contributed to the annual value of $23.4 million for FY2023, which is 4494.25% down from last year.
- Latest data reveals that Pasithea Therapeutics reported Common Equity of $17.8 million as of Q3 2024, which was down 3721.82% from $16.2 million recorded in Q2 2024.
- In the past 5 years, Pasithea Therapeutics' Common Equity ranged from a high of $51.5 million in Q2 2022 and a low of $16.2 million during Q2 2024
- Its 4-year average for Common Equity is $33.8 million, with a median of $35.6 million in 2023.
- Per our database at Business Quant, Pasithea Therapeutics' Common Equity skyrocketed by 18399.68% in 2022 and then plummeted by 5455.14% in 2024.
- Pasithea Therapeutics' Common Equity (Quarter) stood at $51.4 million in 2021, then fell by 17.35% to $42.5 million in 2022, then plummeted by 44.94% to $23.4 million in 2023, then fell by 23.87% to $17.8 million in 2024.
- Its last three reported values are $17.8 million in Q3 2024, $16.2 million for Q2 2024, and $19.9 million during Q1 2024.